

Press release

**OTOFARMA AMONG THE PARTICIPANTS IN THE ROUNDTABLE
“LISTING ON THE STOCK EXCHANGE: A GROWTH OPPORTUNITY”
ORGANIZED BY ELITE – BORSA ITALIANA**

Tuesday, 3 December 2025

4:00 p.m.

Naples, Palazzo Ischitella

Naples, 28 November 2025 – The management of Otofarma is pleased to announce that the Company will take part in the roundtable “Listing on the Stock Exchange: a Growth Opportunity,” scheduled for 3 December at 4:00 p.m. at Palazzo Ischitella in Naples. Giovanna Incarnato Bartolomucci, CEO of Otofarma, will be among the key speakers at the event organized by ELITE – Borsa Italiana.

The afternoon will be dedicated to companies focused on growth, innovation, and access to capital markets. During the roundtable, together with representatives of leading entrepreneurial organizations, the discussion will explore the opportunities offered by the listing process and sustainable development models for Italian companies.

The event will also feature contributions from representatives of the Fondo Cresci al Sud, the Naples Industrial Union, ELITE, and Euronext. This will be a valuable opportunity to engage in dialogue on the future of entrepreneurship and the challenges of the market.

For further information and to register for the event:

<https://admin.eventdrive.com/public/events/84002/website/home>

About Otofarma SpA

Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.

Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist tele-audiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.

Founded by Gennaro Bartolomucci, now Chairman, and led by CEO Giovanna Incarnato Bartolomucci, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.

For more information:

Otofarma S.p.A.- Investor relations

Anna Incarnato Bartolomucci

E-mail: anna.incarnato@otofarma.it

mob: +39 347 0506780

Alantra – Euronext Growth Advisor

E-mail: ega@alantra.com

mob: +39 334 6267242

SEC Newgate – Media Relations

+39 02 624 999 1

Michele Bon – michele.bon@secnewgate.it – +39 338 693 3868

Francesca Brambilla – francesca.brambilla@secnewgate.it – +39 338 627 2146